美国 · SEC FORM 4
Xilio Therapeutics, Inc.
XLO · Nasdaq · CIK 0001840233 · Healthcare · Biotechnology
内部人信号
0 qualifying P purchase groups
当前 180 天评分窗口
0 同一窗口内观察到的 Form 4 交易行
0 sales · 0 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号？
评分构成
活跃窗口内没有合资格买入，因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数？
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示，不会形成负分。
卖出和其他 Form 4 活动会单独显示，不会形成负面买入信号。没有买入不会被评分为看空。
内部人活动时间轴
当前 180 天窗口内没有 Form 4 交易事件。
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后，这些模块才会启用。
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2026-03-26 · Shannon James Samuel.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据，不影响内部人信号。
- 空头股数
- 410,050
- 上期报告
- 412,963
- 日均成交量
- 9,210
- 回补天数
- 44.5
FINRA 结算日：2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数，每月两个结算日之后约一周公布；不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-03-26 | Shannon James Samuel | 买入 (P) | Common Stock | 5,000 | USD 8.79 | USD 43,950 | SEC 申报 ↗ |
| 2025-06-17 | Shannon James Samuel | 买入 (P) | Common Stock | 25,000 | USD 0.69 | USD 17,250 | SEC 申报 ↗ |
| 2025-06-16 | Shannon James Samuel | 买入 (P) | Common Stock | 45,000 | USD 0.69 | USD 31,050 | SEC 申报 ↗ |
| 2025-06-16 | Russo Rene | 买入 (P) | Common Stock | 36,289 | USD 0.68 | USD 24,677 | SEC 申报 ↗ |
| 2024-12-18 | GILEAD SCIENCES, INC. | 买入 (P) | Common Stock | 1,759,978 | USD 1.04 | USD 1,830,377 | SEC 申报 ↗ |
| 2024-04-02 | GILEAD SCIENCES, INC. | 买入 (P) | Common Stock | 485,250 | USD 0.76 | USD 368,790 | SEC 申报 ↗ |
| 2021-12-10 | BCIP Life Sciences Associates, LP; BCLS II Investco, LP; BCLS II Investo (GP), LLC; Bain Capital Life Sciences Fund II, L.P.; Bain Capital Life Sciences Investors II, LLC; Bain Capital Life Sciences Investors, LLC | 买入 (P) | Common Stock | 25,000 | USD 9.65 | USD 241,168 | SEC 申报 ↗ |
| 2021-12-09 | BCIP Life Sciences Associates, LP; BCLS II Investco, LP; BCLS II Investo (GP), LLC; Bain Capital Life Sciences Fund II, L.P.; Bain Capital Life Sciences Investors II, LLC; Bain Capital Life Sciences Investors, LLC | 买入 (P) | Common Stock | 4,011 | USD 9.84 | USD 39,468 | SEC 申报 ↗ |
| 2021-12-08 | BCIP Life Sciences Associates, LP; BCLS II Investco, LP; BCLS II Investo (GP), LLC; Bain Capital Life Sciences Fund II, L.P.; Bain Capital Life Sciences Investors II, LLC; Bain Capital Life Sciences Investors, LLC | 买入 (P) | Common Stock | 13,458 | USD 9.62 | USD 129,466 | SEC 申报 ↗ |
| 2021-10-26 | SV7 (IMF) GP LLP; SV7 Impact Medicine Fund LP | 买入 (P) | Common Stock | 312,500 | USD 16.00 | USD 5,000,000 | SEC 申报 ↗ |
| 2021-10-26 | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C); DEERFIELD PARTNERS, L.P.; Deerfield Mgmt L.P.; Deerfield Mgmt V, L.P.; Flynn James E | 买入 (P) | Common Stock | 387,500 | USD 16.00 | USD 6,200,000 | SEC 申报 ↗ |
| 2021-10-26 | RiverVest Venture Fund IV, L.P. | 买入 (P) | Common Stock | 250,000 | USD 16.00 | USD 4,000,000 | SEC 申报 ↗ |
| 2021-10-26 | Four Pines Master Fund LP; Rock Springs Capital LLC; Rock Springs Capital Management LP; Rock Springs Capital Master Fund LP | 买入 (P) | Common Stock | 500,000 | USD 16.00 | USD 8,000,000 | SEC 申报 ↗ |
| 2021-10-26 | BAY CITY CAPITAL LLC | 买入 (P) | Common Stock | 312,500 | USD 16.00 | USD 5,000,000 | SEC 申报 ↗ |
| 2021-10-26 | Atlas Venture Fund XI, L.P.; Atlas Venture Opportunity Fund I, L.P. | 买入 (P) | Common Stock | 187,500 | USD 16.00 | USD 3,000,000 | SEC 申报 ↗ |
Form 4 申报证据
7 transaction lines in the latest 365-day window; 58 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-03-26 | Shannon James Samuel | 买入 (P) | Common Stock | 5,000 | USD 8.79 | USD 43,950 | SEC 申报 ↗ |
| 2026-01-02 | Frankenfield Christopher James | 卖出 (S) | Common Stock | 7,030 | USD 0.64 | USD 4,499 | SEC 申报 ↗ |
| 2026-01-02 | Brennan Kevin M. | 卖出 (S) | Common Stock | 1,826 | USD 0.64 | USD 1,169 | SEC 申报 ↗ |
展开近期 Form 4 证据 (7 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-03-26 | Shannon James Samuel | 买入 (P) | Common Stock | 5,000 | USD 8.79 | USD 43,950 | SEC 申报 ↗ |
| 2026-01-02 | Frankenfield Christopher James | 卖出 (S) | Common Stock | 7,030 | USD 0.64 | USD 4,499 | SEC 申报 ↗ |
| 2026-01-02 | Brennan Kevin M. | 卖出 (S) | Common Stock | 1,826 | USD 0.64 | USD 1,169 | SEC 申报 ↗ |
| 2026-01-01 | Russo Rene | 期权行权／转换 (M) | Common Stock | 44,250 | USD — | USD — | SEC 申报 ↗ |
| 2026-01-01 | Luptakova Katarina | 期权行权／转换 (M) | Common Stock | 16,625 | USD — | USD — | SEC 申报 ↗ |
| 2026-01-01 | Frankenfield Christopher James | 期权行权／转换 (M) | Common Stock | 19,375 | USD — | USD — | SEC 申报 ↗ |
| 2026-01-01 | Brennan Kevin M. | 期权行权／转换 (M) | Common Stock | 5,000 | USD — | USD — | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-18 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | XLO |
| CIK | 0001840233 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 58 transaction lines from 2021-10-26 to 2026-03-26 16 P purchase lines · 10 S sale lines · 32 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.